NCT03767218View on ClinicalTrials.gov

Initiation of Ovarian Stimulation With Recombinant-human FSH (Bemfola®) in the Late Follicular Phase

PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

May 27, 2022

Study Completion Date

November 25, 2022

Conditions
Infertility, Female
Interventions
COMBINATION_PRODUCT

Late follicular phase stimulation with recombinant-human FSH

Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from the late follicular phase of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH \> 10 IU/L, till day of trigger.

COMBINATION_PRODUCT

Early follicular phase stimulation with recombinant-human FSH

Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.

Trial Locations (1)

1090

Universitair Ziekenhuis Brussel, Brussels

All Listed Sponsors
lead

Universitair Ziekenhuis Brussel

OTHER

NCT03767218 - Initiation of Ovarian Stimulation With Recombinant-human FSH (Bemfola®) in the Late Follicular Phase | Biotech Hunter | Biotech Hunter